No Data
No Data
Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $54
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
H.C. Wainwright Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Cuts Target Price to $56
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Express News | Karyopharm Therapeutics Inc : H.c. Wainwright Adjusts Target Price to $56 From $7 to Reflect 1-for-15 Reverse Stock Split
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending